Shanghai-based medical device conglomerate MicroPort Scientific Corp. (HKG: 0853) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its proprietary bioabsorbable rapamycin eluting coronary stent system. This innovative device is designed for the treatment of patients suffering from ischemic heart disease due to primary coronary artery disease.
The stent system stands out for its single-sided drug coating technology, which selectively applies the drug only to the outer surface of the stent through a dot coating process. This unique approach eliminates drug coating on the side and inner surface of the stent rod, thereby enhancing drug utilization rates and facilitating the crucial process of vascular endothelialization, which is essential for the healing and recovery of the blood vessel lining.- Flcube.com
